Outcome of Emergency Pulmonary Lobectomy under ECMO Support in Patients with COVID-19

Abstract Background  Not much is known about the results of nonelective anatomical lung resections in coronavirus disease 2019 (COVID-19) patients put on extracorporeal membrane oxygenation (ECMO). The aim of this study was to analyze the outcome of lobectomy under ECMO support in patients with acute respiratory failure due to severe COVID-19. Methods  All COVID-19 patients undergoing anatomical lung resection with ECMO support at a German university hospital were included into a prospective database. Study period was April 1, 2020, to April 30, 2021 (first, second, and third waves in Germany). Results  A total of nine patients (median age 61 years, interquartile range 10 years) were included. There was virtually no preexisting comorbidity (median Charlson score of comorbidity 0.2). The mean interval between first positive COVID-19 test and surgery was 21.9 days. Clinical symptoms at the time of surgery were sepsis (nine of nine), respiratory failure (nine of nine), acute renal failure (five of nine), pleural empyema (five of nine), lung artery embolism (four of nine), and pneumothorax (two of nine). Mean intensive care unit (ICU) and ECMO days before surgery were 15.4 and 6, respectively. Indications for surgery were bacterial superinfection with lung abscess formation and progressive septic shock (seven of nine) and abscess formation with massive pulmonary hemorrhage into the abscess cavity (two of nine). All patients were under venovenous ECMO with femoral-jugular configuration. Operative procedures were lobectomy (eight) and pneumonectomy (one). Weaning from ECMO was successful in four of nine. In-hospital mortality was five of nine. Mean total ECMO days were 10.3 ± 6.2 and mean total ICU days were 27.7 ± 9.9. Mean length of stay was 28.7 ± 8.8 days. Conclusion  Emergency surgery under ECMO support seems to open up a perspective for surgical source control in COVID-19 patients with bacterial superinfection and localized pulmonary abscess.

[1]  T. Malfait,et al.  Video-assisted thoracic surgery in critically ill COVID-19 patients on venovenous extracorporeal membrane oxygenation , 2022, Perfusion.

[2]  S. Weber-Carstens,et al.  COVID-19 Patients Require Prolonged Extracorporeal Membrane Oxygenation Support for Survival Compared With Non-COVID-19 Patients , 2022, Critical care explorations.

[3]  L. Camporota,et al.  Survival benefit of extracorporeal membrane oxygenation in severe COVID-19: a multi-centre-matched cohort study , 2022, Intensive Care Medicine.

[4]  Á. Soriano,et al.  Bacterial co-infection at hospital admission in patients with COVID-19 , 2022, International Journal of Infectious Diseases.

[5]  P. Spieth,et al.  Use of extracorporeal membrane oxygenation in non-elective major thoracic surgery for infectious lung abscess. , 2022, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  Ryan P. Barbaro,et al.  Extracorporeal Membrane Oxygenation during Respiratory Pandemics: Past, Present, and Future , 2022, American Journal of Respiratory and Critical Care Medicine.

[7]  R. Cerfolio,et al.  One-Year Outcomes With Venovenous Extracorporeal Membrane Oxygenation Support for Severe COVID-19 , 2022, The Annals of Thoracic Surgery.

[8]  T. Welte,et al.  ECMO during the COVID-19 pandemic: moving from rescue therapy to more reasonable indications , 2022, European Respiratory Journal.

[9]  D. Wichmann,et al.  The prevalence of early‐ and late‐onset bacterial, viral, and fungal respiratory superinfections in invasively ventilated COVID‐19 patients , 2021, Journal of medical virology.

[10]  Stephan Luna,et al.  Risk factors for mortality in patients with COVID-19 needing extracorporeal respiratory support , 2021, European Respiratory Journal.

[11]  S. Bhattacharyya,et al.  Respiratory Pathogen Coinfections in SARS-CoV-2-Positive Patients in Southeastern Wisconsin: A Retrospective Analysis , 2021, Microbiology spectrum.

[12]  S. Silvestry,et al.  Extracorporeal membrane oxygenation support during the coronavirus disease 2019 pandemic: Outcomes and technical considerations , 2021, JTCVS Open.

[13]  F. Maisano,et al.  ECMO therapy in COVID‐19: An experience from Zurich , 2021 .

[14]  R. Cerfolio,et al.  Thoracic surgery outcomes for patients with Coronavirus Disease 2019 , 2021, The Journal of Thoracic and Cardiovascular Surgery.

[15]  T. Nebreda-Mayoral,et al.  Bacterial/fungal infection in hospitalized patients with COVID-19 in a tertiary hospital in the Community of Castilla y León, Spain. , 2020, Enfermedades infecciosas y microbiologia clinica.

[16]  A. Moreira,et al.  Lobectomy for Hemorrhagic Lobar Infarction in a Patient With COVID-19 , 2020, The Annals of Thoracic Surgery.

[17]  A. Mariani,et al.  Thoracic surgery in a hospital dedicated to treating COVID-19: challenges and solutions , 2020, Clinics.

[18]  Kiran Shekar,et al.  Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases , 2020, The Lancet Respiratory Medicine.

[19]  M. de Perrot,et al.  Principles and indications of extracorporeal life support in general thoracic surgery. , 2018, Journal of thoracic disease.

[20]  F. Pappalardo,et al.  Weaning from veno-venous extracorporeal membrane oxygenation: how I do it. , 2018, Journal of thoracic disease.

[21]  R. Karmy-Jones,et al.  Predictors of Outcome in Modern Surgery for Lung Abscess , 2017, The Thoracic and Cardiovascular Surgeon.

[22]  A. Lejay,et al.  Vascular access for extracorporeal life support: tips and tricks. , 2016, Journal of thoracic disease.

[23]  N. Harunari,et al.  Gauze packing as damage control for uncontrollable haemorrhage in severe thoracic trauma , 2013, Annals of the Royal College of Surgeons of England.

[24]  Anthony S Fauci,et al.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. , 2008, The Journal of infectious diseases.